CSL Ltd (CSL) develops, manufactures, markets and distributes plasma protein biotherapies to treat and prevent serious human medical conditions and vaccines for the prevention and treatment of serious diseases. The company focuses on conditions related to hematology, respiratory, cardiovascular, metabolic, nephrology and transplant, immunology and vaccines, among others.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

CSL leads development in groundbreaking products and enhancing manufacturing processes to protect public health. The company's R&D efforts focus on scientific excellence, aiming at innovations in various therapeutic areas. CSL’s broad pipeline includes promising candidates in the fields of immunology, hematology, respiratory, cardiovascular and metabolic, nephrology and transplant, besides vaccines. The products under development include Garadacimab, Hizentra, Anumigilumab in immunology, and CSL400 through CSL406 in vaccines. The company also manages several out-licensed programs targeting significant medical needs. These include Eblasakimab for Atopic Dermatitis, Mavrilimumab for Giant Cell Arthritis and Rheumatoid Arthritis, and LASN01 for Idiopathic Pulmonary Fibrosis and Thyroid Eye Disease. The company emphasizes a quantitative approach to understanding diseases at a molecular and cellular level, combined with a deep understanding of clinical and commercial aspects. CSL Ltd's R&D focuses on four strategic platforms: plasma protein technology, recombinant technology, genetic medicine, and vaccines technology. These initiatives aim to develop and deliver innovative medicines and vaccines that address unmet medical needs, prevent infectious diseases, and protect public health. These partnerships extend CSL’s impact beyond its internal research pipeline, highlighting its role in advancing treatment options through strategic external collaborations. CSL’s R&D division, which includes around 2,500 employees in biotechnology hubs in 10 countries, is pivotal to its innovation strategy. The division actively engages in partnerships with universities, research institutions, and pharmaceutical companies for progress in biomedical research. To strengthen its innovation efforts, CSL has formed strategic alliances with various incubators, accelerators, and venture funders. In Australia, CSL’s exclusive investment in the Brandon BioCatalyst Fund 6 aids early-stage biomedical discoveries. This collaboration provides CSL access to a network of over 50 research institutions, enhancing its capability to discover and develop new treatments. In FY2024, CSL conducted 60 clinical trials in various therapeutic areas. This facility will house more than 850 professionals for advancing CSL’s mission. Internationally, CSL has extended its partnership with BaseLaunch and established an R&D office at Biopole’s Lausanne campus. In April 2025, the Jumar Bioincubator, inaugurated in April 2025, assists biotech start-ups and intends to strengthen CSL’s biomedical network, furthering its commitment to innovation and collaboration. In FY2025, the company's R&D expenses stood at US$1,359 million.